Skip to content
New: Explore the psychedelic pipeline via our Q3'25 🎯 Bullseye Charts.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in

Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

Atai Life Sciences Logo White

ATAI Life Sciences

Beckley Psytech Company Profile

Beckley Psytech

Better Plant Sciences Company Profile

Better Plant Sciences (PLNT)

CaaMTech Company Profile

CaaMTech

Champignon Brands Company Profile

Champignon Brands Inc. (SHRM)

Compass Pathways Company Profile

COMPASS Pathways (CMPS)

Cybin Company Profile

Cybin Inc.

Eleusis Company Profile

Eleusis

Entheon Biomedical

Field Trip FTRP Company Profile

Field Trip (FTRP)

Havn Life Company Profile

Havn Life (HAVN)

Hollister Biosciences Company Profile

Hollister Biosciences (HOLL)

MagicMed Company Profile

MagicMed Industries

MindMed MMED Company Profile

MindMed (MMED)

Mydecine Innovations Company Profile

Mydecine Innovations Group (MYCO)

Numinus Company Profile

Numinus (NUMI)

Revive Therapeutics Company Profile

Revive Therapeutics Ltd. (RVV)

AI-powered Search

Your Pα+ account

Sign in

Quick Links

  • InsightsOpens in a new tab
  • JobsOpens in a new tab
  • DataOpens in a new tab
  • Subscribe to Pα+Opens in a new tab
  • ContactOpens in a new tab
  • Q3’25 Psychedelic Drug Development Pipeline: Bullseye ChartsSeptember 16, 2025
  • ‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance
    ‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic RenaissanceSeptember 11, 2025
  • August 2025 psychedelic patent update
    August 2025 Psychedelic Patent UpdateSeptember 9, 2025
  • Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos
    Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for LykosSeptember 8, 2025
  • Bulletin 208
    Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts DrysdaleSeptember 5, 2025

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More